| Source: | Penicillium
sp. |
| Synonyms | Citreoviridin A
4-Methoxy-5-methyl-6-(7-methyl-8-(tetrahydro-3,4-dihydroxy-2,4,5-trimethyl-2-furyl)-1,3,5,7-octatetraenyl)-2H-pyran-2-one |
| Description: |
Neurotoxic mycotoxin from Penicillium toxicarium,
Penicillium ochrosalmoneum, Penicillium
ochrosalmoneum, Aspergillus terreus,
Penicillium citreo-viride and several other
related fungi. Citreoviridin is believed to be the cause of the Acute Cardiac Beri-Beri disease. |
| CAS number: | 25425-12-1 |
| Merck index: | 14: Not
listed |
| Molecular weight: | 412 |
| Structure: |
Citreoviridin
 |
| Molecular Formula: | C23H30O6 |
| Canonical SMILES: |
CC1C(C(C(O1)(C)C=C(C)C=CC=CC=CC2=C(C(=CC(=O)O2)OC)C)O)(C)O |
Solubility
information: | Citreoviridin
is soluble in benzene, ethanol, chloroform, ether,
dichloromethane. Citreoviridin is hardly
soluble in water (enough to give it yellow color) and hexane |
| Specifications |
|
| Appearance: |
Orange-yellow powder |
| Purity: | At least 97% by TLC, HPLC
|
| λmax: |
390, 294, 204nm |
| Melting point | 110°C |
| Solubility | 10 mg of
Citreoviridin gives clear yellow solution in 1 ml of DMSO, Methanol,
Dichloromethane. |
| Storage | -18°C, PROTECT
FROM LIGHT |
| Applications | As other Aurovertin group members, Citreoviridin
binds to and inhibit mitochondrial ATPase, thereby
uncoupling oxidative phosphorylation.
Aurovertins are used as biochemical tools. |
| Warnings | |
| Classification |
Aurovertin class mycotoxin |
| Related products | |
| | For Research use only. Not for Human or Drug use
GMP/API grade available on request
Citreoviridin by Fermentek is not produced from or contains any ingredients from animal origin.
No genetically modified organisms are used. |
| Publications | |
| | Vieta I, Savarino A, Papa G, Vidotto V,
Cantamessa C, Pugliese A.
In vitro inhibitory activity of citreoviridin against HIV-1
and an HIV-associated opportunist: Candida albicans.
J Chemother. 1996 Oct;8(5):351-7 |
| | Sayood SF, Suh H, Wilcox CS,
Schuster SM.
Effect of citreoviridin and
isocitreoviridin on beef heart mitochondrial ATPase.
Arch Biochem Biophys. 1989 May 1;270(2):714-21. |
| | Wicklow DT, Stubblefield RD, Horn
BW, Shotwell OL.
Citreoviridin levels in
Eupenicillium ochrosalmoneum-infested maize kernels at harvest.
Appl Environ Microbiol. 1988 May;54(5):1096-8. |
| | Nishie K, Cole RJ, Dorner JW.
Toxicity of citreoviridin.
Res Commun Chem Pathol Pharmacol. 1988 Jan;59(1):31-52. |
| | Gause EM, Buck MA, Douglas MG.
Binding of citreoviridin to
the beta subunit of the yeast F1-ATPase.
J Biol Chem. 1981 Jan 25;256(2):557-9. |
| | Satre M, Bof M, Vignais PV.
Interaction of Escherichia
coli adenosine triphosphatase with aurovertin and citreoviridin: inhibition
and fluorescence studies.
J Bacteriol. 1980 Jun;142(3):768-76. |
| | Linnett PE, Mitchell AD, Osselton
MD, Mulheirn LJ, Beechey RB.
Citreoviridin, a specific
inhibitor of the mitochondiral adenosine triphosphatase.
Biochem J. 1978 Mar 15;170(3):503-10. |
|
Aspergillus tereus, one of the Citreoviridin producers |
| Citreoviridin clinical potential
...The
present invention relates to the compositions and methods for the inhibition
of cellular proliferation. More particularly, the present invention relates
to the use of antibiotics such as efrapeptins, oligomycins, mycotoxins, or
mycotoxin derivatives including those comprising aurovertin B, citreoviridin,
and α-zearalenol structural motifs for the treatment of hyperproliferative
diseases such as cancer, atherosclerosis, and psoriasis...
US Patent 6528489 - Mycotoxin derivatives as antimitotic agents |
 |
|
